Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression

Table 1 Protocol reproducibility with the optimized clinical-grade compatible conditions using buffy coats from eight donor pairs

	CD14⁺ purity (%)	DC-10 yield (%)	CD4⁺ purity (%)	T₁₀-cell yield (%)	Donor-specific anergy (%)
Mean	95	13	98	53	80
SD	3	6	1	31	10
Range	90–99	4–21	97–99	17–123	63–94
CV	3.3	47.3	0.9	59.0	14.6

DC-10 tolerogenic dendritic cells, SD standard deviation, CV coefficient of variation

ISSN: 1479-5876